SPRC (SciSparc) PEG Ratio: N/A (As of Aug. 28, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SPRC SciSparc Ltd SPRC
39 GF Score
Price $6.66
GF Value $3.03
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is SciSparc PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, SciSparc's PE Ratio without NRI is 0.00. SciSparc's 5-Year EBITDA growth rate is -24.00%. Therefore, SciSparc's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for SciSparc's PEG Ratio or its related term are showing as below:



SPRC's PEG Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.68
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


SciSparc  (NAS:SPRC) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


SciSparc PEG Ratio Related Terms


SciSparc PEG Ratio Historical Data

* Premium members only.

The historical data trend for SciSparc's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SciSparc PEG Ratio Chart

SciSparc Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

SciSparc Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

SPRC vs ACUT, ONCO, PPCB: PEG Ratio Comparison

For the Biotechnology subindustry, SciSparc's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SciSparc PEG Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SciSparc's PEG Ratio distribution charts can be found below:

* The bar in red indicates where SciSparc's PEG Ratio falls into.


SPRC
39GF Score
SciSparc Ltd SPRC
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SciSparc PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

SciSparc's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/-24.00
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Is SciSparc (SPRC) Overvalued in 2026?

Based on GuruFocus' analysis, SciSparc stock appears to be overvalued. The current stock price of $6.66 is trading 119.8% above its estimated GF Value™ of $3.03. GuruFocus considers SciSparc to be Significantly Overvalued.

Key valuation signals for SPRC:

  • PEG Ratio: N/A
  • GF Value™: $3.03 vs. price of $6.66 (119.8% above fair value)
  • GF Score™: 39/100 with 8 warning signs

No single metric tells the full story. See the SPRC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


SciSparc Business Description

Address 20 Raul Wallenberg Street, Tower A, 2nd Floor, Tel Aviv, ISR, 6971916
SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two operating reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
39GF Score

Get the complete analysis for SPRC

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.66
Price
$3.03
GF Value